Ardelyx Inc(ARDX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 26 at 7:39 PM ET (Korea 10/27 08:39)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.23 | Insider Own | 3.91% | Shs Outstand | 249.2M | Perf Week | -2.91% |
| Market Cap | 0.75B | Forward P/E | 11.86 | EPS next Y | 241.21% | Insider Trans | -4.13% | Shs Float | 239.4M | Perf Month | -12.28% |
| Enterprise Value | 0.72B | PEG | - | EPS next Q | -0.01 | Inst Own | 71.71% | Short Float | 11.56% | Perf Quarter | -41% |
| Income | -0.06B | P/S | 1.66 | EPS this Y | 31.08% | Inst Trans | -1.29% | Short Ratio | 6.29 | Perf Half Y | -49.92% |
| Sales | 0.45B | P/B | 5.02 | EPS next 5Y | - | ROA | -10.68% | Short Interest | 27.68M | Perf YTD | -48.54% |
| Book/sh | 0.6 | P/C | 2.65 | EPS past 3/5Y | 15.49% 24.66% | ROE | -38.61% | 52W High | -64.29% ($8.40) | Perf Year | -40.48% |
| Cash/sh | 1.13 | P/FCF | - | Sales past 3/5Y | 98.4% 121.9% | ROIC | -13.8% | 52W Low | -0.66% ($3.02) | Perf 3Y | -16.67% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 4.11% | Gross Margin | 93.62% | Volatility(W/M) | 4.37% 4% | Perf 5Y | 160.87% |
| Dividend TTM | - | EV/Sales | 1.6 | Sales Y/Y TTM | 16.77% | Oper. Margin | -7.86% | ATR (14) | 0.13 | Perf 10Y | -77.7% |
| Dividend Ex-Date | - | Quick Ratio | 3.15 | EPS Q/Q | 15.22% | Profit Margin | -12.35% | RSI (14) | 33.53 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.34 | Sales Q/Q | 23.77% | SMA20 | -7.19% ($3.23) | Beta | 0.77 | Target Price | $12.8 |
| Payout | - | Debt/Eq | 1.72 | Earnings | 2026/11/3 | SMA50 | -14.3% ($3.5) | Rel Volume | 1.14 | Prev Close | $3.08 |
| Employees | 489 | LT Debt/Eq | 1.71 | EPS/Sales Surpr. | -6.87% -0.13% | SMA200 | -44.64% ($5.42) | Avg Volume(3M) | 4.40M | Price | $3 |
| IPO | 2014/6/19 | Option/Short | Yes/Yes | Trades | 9804 | Volume | 5,000,637 | Change | -2.6% |
💊 Ardelyx (ARDX) is a U.S. biopharmaceutical company that develops and commercializes treatments for cardio-renal and gastrointestinal diseases. Built around its lead molecule tenapanor, Ardelyx has two marketed products: IBSRELA, a treatment for irritable bowel syndrome with constipation, and XPHOZAH, a treatment for hyperphosphatemia in patients on dialysis. The company is a commercial-stage pharmaceutical business moving toward revenue growth and a clear path to profitability.
Over the past 1 year, on the lower side
64% below its 1-year high.
Traded about as much as usual. That is 114% of its average volume.
Next earnings report: November 3
7 days to go.
ARDX has a sound balance sheet but weak earning power
Of every $100 in sales, $7.86 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +31.1% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $166. Peers typically go for $1,213.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +160.9%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 71.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #178 of 594 in the industry
Based on market cap of $748M.
APMD#175 Apnimed Inc $789M PER - 
AVBP#176 ArriVent BioPharma Inc $757M PER - 
HELP#177 Helus Pharma Inc $757M PER - ARDX#178 Ardelyx Inc $748M PER - 
GERN#179 Geron Corp $739M PER - 
FAQ
What kind of company is ARDX?
ARDX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ARDX?
The market cap of ARDX is approximately $748M, ranking 2,784 within its sector.
What is the 52-week high and low for ARDX?
ARDX has recorded a 52-week high of $8.40 and a low of $3.02.
